Drug Information

Drug General Information
Drug ID
D0MG2R
Former ID
DIB005803
Drug Name
ALX-0141
Synonyms
Nanobody therapeutic (bone disease), Ablynx; Nanobody therapeutic (osteoporosis), Ablynx
Indication Osteoporosis [ICD9: 733.0, V07.4; ICD10:M80-M81, Z79.890] Phase 1 [549005]
Company
Ablynx NV
Target and Pathway
Target(s) Tumor necrosis factor ligand superfamily member 11 Target Info Inhibitor [550190]
KEGG Pathway Cytokine-cytokine receptor interaction
NF-kappa B signaling pathway
Osteoclast differentiation
Prolactin signaling pathway
Rheumatoid arthritis
NetPath Pathway Leptin Signaling Pathway
TWEAK Signaling Pathway
Pathway Interaction Database IL6-mediated signaling events
Reactome TNFR2 non-canonical NF-kB pathway
TNFs bind their physiological receptors
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
WikiPathways Osteoblast Signaling
Vitamin D Receptor Pathway
Differentiation Pathway
RANKL/RANK Signaling Pathway
Osteoclast Signaling
References
Ref 549005Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031383)
Ref 550190Clinical pipeline report, company report or official report of Ablynx.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.